ClinicalTrials.gg
RecruitingNCT05976347Updated May 22, 2026

Identifying and Treating Depression in the Orthopaedic Trauma Population

A Phase 4 interventional study of Fluoxetine 20 MG and Duloxetine 30 MG in Depression, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.

Planned enrollment
21st of 42
100 · median 97
Started
2025
with 4 others
Phase 4
9 of 43
3 open now
Registered
36th of 43
by date

Among the 43 studies testing fluoxetine in Depression, this one is the 21st largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 in phase 4, and was the 36th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About fluoxetine

Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing fluoxetine in Depression, or all of them as a file.
02

Study summary

The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are:

  1. What are the outcomes of patients who screen positive for depressive symptoms and are prescribed either an Selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI).
  2. What are the outcomes of patients who screen positive for depressive symptoms and choose not to pursue treatment with medication?
Read the detailed description

Depression is common among orthopaedic trauma patients and associated with worsened outcomes including pain, opioid consumption, patient-reported outcomes ,complications, and length of stay. Addressing depression, therefore, should lead to improved outcomes. Orthopaedic surgeons may believe treating depression is outside their scope or that they lack tools to address depressive symptoms. In fact, only 45% of surgeons report they are likely to screen patients, and only 27% are likely to refer patients for psychological treatment.

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting to an Orthopaedic trauma clinic for the first time following operative extremity fracture or any pelvis fracture
  • A score of greater than or equal to 5 on the Patient Health Questionnaire-9 (PHQ-9) at first post- operative visit
  • Age 18 or older
  • Speak English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Currently taking medication to treat depression
  • /allergy to one of the study medications
  • Bipolar disorder of psychotic disorder
  • Endorse suicidal ideation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Selective serotonin reuptake inhibitors (SSRI)

    Fluoxetine, 20mg once daily

    Drug: Fluoxetine 20 MG

  • Experimental
    serotonin and norepinephrine reuptake inhibitors (SNRI)

    Duloxetine, 30mg once daily

    Drug: Duloxetine 30 MG

  • Other
    Observational

    Referral to behavioral health per standard practice and provision of resources for strategices to address depressive symptoms.

    Other: Observation

Interventions

  • DrugFluoxetineStudies of FluoxetineFluoxetine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fluoxetine 20 mg once daily

    Also known as: Prozac Weekly, Sarafem, Prozac

  • DrugDuloxetineStudies of DuloxetineDuloxetine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Duloxetine 30 mg once daily

    Also known as: Irenka and Cymbalta

  • OtherObservation

    Referral to behavioral health and resources for addressing depressive symptoms

    Also known as: Referral to behavioral health and resources

06

What researchers measure

Primary outcomes

  1. Depressive Symptom Scores

    Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.

    Time frame: Baseline

  2. Depressive Symptom Scores

    Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.

    Time frame: Month 3

  3. Depressive Symptom Scores

    Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.

    Time frame: Month 6

  4. Depressive Symptom Scores

    Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.

    Time frame: Month 9

  5. Depressive Symptom Scores

    Improvement in depressive symptoms, indication by either remission (PHQ-9 score \<5) or a 50% reduction in PHQ-9 score. The Patient Health Questionnaire (PHQ-9) is a self-report tool that incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms. The too rates the frequency of the symptoms which factors into the scoring severity index. PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe depression.

    Time frame: Year 1

Secondary outcomes

  1. Adherence to Treatment Percentage

    Adherence to treatment and side effects or adverse events associated with the medications will be collected using patient logs, study visit questionnaires, and the medical record (i.e., number of prescriptions filled).

    Time frame: Months 3, 6, and 12

  2. Utilization of non-pharmaceutical tools and resources Percentage

    Engagement with behavioral health resources will be collected using patient logs, study visit questionnaires, and the medical record (i.e., number of visits with Behavioral Health).

    Time frame: Months 3, 6, and 12

  3. Patient Reported Outcome Measures - PROMIS-29 Scores

    The PROMIS-29 scales will be scored using a T-score metric method. A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores mean a higher level of disability.

    Time frame: Months 3, 6, and 12

  4. Patient Reported Outcome Measures - Work Productivity and Activity Impairment Questionnaire Scores

    The Work Productivity and Activity Impairment questionnaire measures how work productivity and activities are impaired by a specific health condition or disease. Scores are expressed as a percentage of impairment/productivity loss, a high score indicates greater impairment.

    Time frame: Months 3, 6, and 12

  5. Patient Reported Outcome Measures - Brief Pain Inventory Scores

    Assesses the severity of pain and the impact of pain on daily functions. Assesses the severity of and impact of pain on daily function. Patients are asked to rate their current symptoms, average experiences of pain, and the minimum and maximum intensities of their symptoms on scales that range from 1-10. A total pain severity score can be found by averaging these items or a single items can be treated as the primary outcome. Higher scores indicate greater severity and more interference.

    Time frame: Months 3, 6, and 12

  6. Healthcare Utilization - The number of hospitalizations and ED visits

    The number of hospitalizations and ED visits

    Time frame: Months 3, 6, and 12

  7. Patient Reported Outcome Measures: Patient Health Questionnaire 9 (PHQ-9)

    A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression. The higher the score, the more symptoms of depression experienced, and the more severe the depression is.

    Time frame: Months 3, 6, and 12

  8. Patient Reported Outcome Measures - Veterans RAND 12 Item Health Survey (VR-12)

    Measures health related quality of life across 7 domains. The answers are summarized into two scores - a Physical Component Score and a Mental Component Score.

    Time frame: Months 3, 6, and 12

  9. Qualitative Interview Information

    Patients in the observational arm will participate in semi-structured interviews. Interviews will be recorded and transcribed verbatim within one week. Field notes will be written within one week of each interview, and the interview guide will be revised as appropriate.

    Time frame: One time between 6-12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 23 months is below that.

Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 4, 2023
StartActual
Jun 25, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05976347
Responsible party
Sponsor
First posted
Aug 4, 2023
Start date
Jun 25, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
May 22, 2026

Study contacts

Erica Grochowski, MPH
Contact
Erica.Grochowski@advocatehealth.org
704-403-4980
Meghan K Wally, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluoxetine · Duloxetine

Start the discussion